This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Cardiovascular Diabetology
JULY 22, 2024
Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mec.
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold
52 
DAIC
MAY 6, 2024
The primary outcome measure for the study is change in six-minute walk distance from Baseline to Week 12. Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V.
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
American College of Cardiology
NOVEMBER 7, 2024
The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.
American College of Cardiology
JULY 8, 2024
The goal of the PARAGON-HF trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril/valsartan among patients with heart failure with preserved ejection fraction (HFpEF).
Heart BMJ
MARCH 26, 2025
1 Left ventricular ejection fraction (LVEF) is a crucial parameter in HF assessment and management, although the differences in mortality are little different between HF with LVEF≥50% or HF with preserved ejection fraction (HFpEF) in patients with post-MI compared with HF with LVEF≤40% or HF with reduced ejection fraction (HFrEF).
The British Journal of Cardiology
APRIL 2, 2025
All services reviewed patients with HF with reduced ejection fraction (HFrEF), only 58% reviewed patients with HF with preserved ejection fraction (HFpEF). Studies are needed to determine if they are adequately resourced to meet population needs and improve patient outcomes.
HeartRhythm
OCTOBER 21, 2024
Clinical outcomes among patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.
HeartRhythm
JANUARY 6, 2025
The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1]. However, the real-world data on the impact of AF ablation in heart failure with preserved ejection fraction (HFpEF) is not well-established.
Frontiers in Cardiovascular Medicine
JANUARY 28, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology.
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
European Journal of Heart Failure
OCTOBER 30, 2023
In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF). After a median follow-up of 4.6 years,
HeartRhythm
SEPTEMBER 25, 2024
The HFA–PEFF score comprising echocardiographic and laboratory data is designed to diagnose heart failure with preserved ejection fraction and holds prognostic value in patients who underwent catheter ablation for atrial fibrillation (AF). However, the incorporation of many variables into this score limits its practical use.
European Journal of Heart Failure
APRIL 17, 2024
HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. Abstract Mitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF). This is partly due to the inherent heterogeneity of patients with HFpEF.
European Journal of Heart Failure
FEBRUARY 25, 2025
Differences in heart failure with preserved ejection fraction (HFpEF) management across medical specialties. A large majority of HFpEF patients are cared by non-cardiologists.
HeartRhythm
APRIL 30, 2024
Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heart failure with preserved ejection fraction (HFpEF). The majority of these studies evaluated paroxysmal AF cases.
HeartRhythm
APRIL 30, 2024
Patients with heart failure with preserved ejection fraction (HFpEF) have many comorbidities including SND, but the optimal treatment approach for HFpEF with SND is uncertain. Guidelines recommend permanent pacemaker (PPM) implantation in patients with sinus node dysfunction (SND) to improve quality of life.
Heart BMJ
FEBRUARY 12, 2024
Objective Heart failure with preserved ejection fraction (HFpEF) is a common heterogeneous syndrome that remains imprecisely defined and consequently has limited treatment options and poor outcomes. The study will develop a large, highly characterised cohort of patients with HFpEF.
European Journal of Heart Failure
OCTOBER 30, 2023
2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest. Abstract Aims Pulmonary capillary wedge pressure (PAWP) ≥25 mmHg during bicycle ergometry is recommended to uncover occult heart failure with preserved ejection fraction.
Circulation
NOVEMBER 11, 2024
As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Background:Opioid use has increased significantly in the past few decades, impacting cardiac and non-cardiac patients.
Med Page Today
SEPTEMBER 1, 2024
(MedPage Today) -- LONDON -- The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) improved outcomes driven by soft endpoints in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF.
Nature Reviews - Cardiology
SEPTEMBER 18, 2024
Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01087-x The non-steroidal mineralocorticoid receptor antagonist finerenone reduces the risk of adverse outcomes in patients with heart failure with mildly reduced ejection fraction or with preserved ejection fraction, according to findings presented at the ESC Congress (..)
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome characterized by heterogeneous pathophysiology and dynamic changes in cardiac structure and function. Circulation, Volume 150, Issue Suppl_1 , Page A4121812-A4121812, November 12, 2024. The cohort had a median age of 69 years, was 57.5%
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Overall, 60.9% of patients had BMI ≥30 kg/m 2.
American College of Cardiology
FEBRUARY 23, 2024
What is the prevalence of subclinical atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF), and how does it impact outcomes?
European Journal of Heart Failure
DECEMBER 28, 2023
Abstract Background and aim Heart Failure with preserved Ejection Fraction (HFpEF) remains under-diagnosed in clinical practice despite accounting for nearly half of all Heart Hailure (HF) cases. We collected demographic, clinical, echocardiographic and outcome data from the EHR.
Journal of the American Heart Association
DECEMBER 29, 2023
BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. Journal of the American Heart Association, Ahead of Print.
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
Cardiovascular Diabetology
FEBRUARY 12, 2024
However, its implications specifically in HF with preserved ejection fr. Recent studies highlighted that stress hyperglycemia ratio (SHR) is a potential predictor for future risk in heart failure (HF) patients.
Journal of Cardiovascular Electrophysiology
FEBRUARY 13, 2024
Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist.
Cardiovascular Diabetology
SEPTEMBER 10, 2024
Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
European Journal of Heart Failure
NOVEMBER 29, 2023
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
HeartRhythm
MAY 22, 2024
The combined effect of left ventricular ejection fraction (LVEF) and atrial fibrillation (AF) on clinical outcomes in heart failure (HF) remains complex.
American College of Cardiology
APRIL 4, 2024
Can clinical outcomes be accurately predicted for patients with heart failure and preserved ejection fraction (HFpEF) using routinely collected variables?
HeartRhythm
APRIL 30, 2024
The combined effect of Left Ventricular Ejection Fraction (LVEF) and the presence of Atrial Fibrillation (AF) on clinical outcomes in heart failure (HF) patients remains complex.
HeartRhythm
APRIL 30, 2024
Early heart failure (HF) diagnosis would likely improve clinical outcomes, however over 60% of patients are first diagnosed with HF in the emergency department. ECG-based HF screening has been limited to determination of whether the left ventricular ejection fraction (LVEF) is greater than or less than a threshold value such as 40%.
HeartRhythm
APRIL 30, 2024
A number of studies have examined the impact of atrial fibrillation (AF) ablation on outcomes in heart failure (HF) with reduced ejection (HFrEF) patients. In contrast, data from HF with preserved ejection fraction (HFpEF) patients is limited to small outcome studies and less robust meta-analyses.
HeartRhythm
OCTOBER 18, 2024
The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains unclear.
HeartRhythm
APRIL 30, 2024
Overtime, various studies have reported variable mortality outcomes in heart failure with preserved ejection fraction (HFpEF) patients. It remains unclear to what extent atrial fibrillation (AF) creates increased mortality alone or in combination with either HFpEF or heart failure with reduced ejection fraction (HFrEF).
HeartRhythm
SEPTEMBER 4, 2024
Recent data suggest that sodium-glucose contransporter-2 inhibitors (SGLT2i) may mitigate development of cardiac arrythmias in patients with heart failure with preserved ejection fraction and patients with ischemic heart disease [1].
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.
JAMA Cardiology
NOVEMBER 11, 2023
This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates the association of initial changes in estimated glomerular filtration rate with cardiovascular and kidney outcomes in patients with heart failure and mildly reduced (..)
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content